Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb;37(5):e2413210.
doi: 10.1002/adma.202413210. Epub 2024 Dec 15.

Tumor-Targeted Catalytic Immunotherapy

Affiliations
Review

Tumor-Targeted Catalytic Immunotherapy

En-Li Yang et al. Adv Mater. 2025 Feb.

Abstract

Cancer immunotherapy holds significant promise for improving cancer treatment efficacy; however, the low response rate remains a considerable challenge. To overcome this limitation, advanced catalytic materials offer potential in augmenting catalytic immunotherapy by modulating the immunosuppressive tumor microenvironment (TME) through precise biochemical reactions. Achieving optimal targeting precision and therapeutic efficacy necessitates a thorough understanding of the properties and underlying mechanisms of tumor-targeted catalytic materials. This review provides a comprehensive and systematic overview of recent advancements in tumor-targeted catalytic materials and their critical role in enhancing catalytic immunotherapy. It highlights the types of catalytic reactions, the construction strategies of catalytic materials, and their fundamental mechanisms for tumor targeting, including passive, bioactive, stimuli-responsive, and biomimetic targeting approaches. Furthermore, this review outlines various tumor-specific targeting strategies, encompassing tumor tissue, tumor cell, exogenous stimuli-responsive, TME-responsive, and cellular TME targeting strategies. Finally, the discussion addresses the challenges and future perspectives for transitioning catalytic materials into clinical applications, offering insights that pave the way for next-generation cancer therapies and provide substantial benefits to patients in clinical settings.

Keywords: cancer immunotherapy; catalytic material; targeted therapy; tumor microenvironment.

PubMed Disclaimer

References

    1. J. Galon, D. Bruni, Nat Rev Drug Discov 2019, 18, 197.
    1. L. B. Kennedy, A. K. S. Salama, CA Cancer J Clin 2020, 70, 86.
    1. P. S. Hegde, D. S. Chen, Immunity 2020, 52, 17.
    1. S. Kumagai, K. Itahashi, H. Nishikawa, Nat. Rev. Clin. Oncol. 2024, 21, 337.
    1. K. Li, H. Shi, B. Zhang, X. Ou, Q. Ma, Y. Chen, P. Shu, D. Li, Y. Wang, Signal Transduct Target Ther 2021, 6, 362.

LinkOut - more resources